-
(S)-Mephenytoin: CYP2C19 Substrate for Human Drug Metabolism
2026-06-27
(S)-Mephenytoin is a validated CYP2C19 substrate widely used in cytochrome P450 metabolism and pharmacokinetic studies. Its mechanistic specificity and well-documented parameters make it a benchmark tool for human-relevant in vitro drug metabolism research.
-
Indomethacin in Inflammation Research: Protocols and Innovat
2026-06-26
Indomethacin’s dual action as a Cox-1 selective inhibitor and PPARγ agonist empowers cutting-edge inflammation and lipid metabolism studies. This article details advanced workflows, troubleshooting guidance, and practical insights for leveraging Indomethacin from APExBIO in membrane signaling and anti-inflammatory drug research.
-
hiPSC-Derived Intestinal Organoids for CYP2C19 Substrate Stu
2026-06-26
This study introduces a streamlined protocol for generating human induced pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) suitable for pharmacokinetic research. By enabling long-term expansion and functional differentiation of enterocytes that express drug-metabolizing enzymes, the model advances in vitro evaluation of CYP2C19 substrates such as (S)-Mephenytoin, addressing key limitations of traditional systems.
-
Phosbind Acrylamide: Precision Phosphate-Binding Reagent for
2026-06-25
Phosbind Acrylamide is a specialized phosphate-binding reagent enabling precise, antibody-free protein phosphorylation analysis via SDS-PAGE. It distinguishes phosphorylated from non-phosphorylated proteins through MnCl2-mediated binding, supporting sensitive detection and workflow efficiency. The reagent is optimal for targets in the 30–130 kDa range and operates at neutral physiological pH.
-
(S)-Mephenytoin as a Precision CYP2C19 Substrate for In Vitr
2026-06-25
(S)-Mephenytoin enables precise measurement of CYP2C19-mediated drug metabolism in advanced in vitro models, including human intestinal organoids. This article bridges protocol innovation, troubleshooting, and benchmarking insights, empowering researchers to elevate pharmacokinetic studies using APExBIO's high-purity substrate.
-
Bacillus Strains and Media Shape γ-Glutamyl Peptide Synthesi
2026-06-24
This study rigorously evaluates how different Bacillus strains and growth media control the synthesis of γ-glutamyl peptides, including γ-Glu-Cys, with implications for targeted peptide production and food flavor enhancement. The findings establish that medium composition exerts a stronger influence than strain selection, guiding future research in glutathione metabolism and kokumi-active peptide engineering.
-
(+)-Bicuculline: Technical Guidance for GABAA Antagonist Use
2026-06-23
(+)-Bicuculline is a classical GABAA receptor antagonist for dissecting inhibitory neurotransmission and synaptic NMDA receptor signaling in neuroscience research. It is not suitable for diagnostic or therapeutic use, and reliable results require strict adherence to solubility and storage protocols.
-
AZ505: A SMYD2 Inhibitor Transforming Epigenetic Disease Res
2026-06-23
AZ505, a potent and selective SMYD2 inhibitor from APExBIO, is reshaping translational epigenetic research with its high specificity and robust performance in cellular and disease models. Its use in renal fibrosis and cancer workflows streamlines mechanistic assays and opens new directions for targeted intervention.
-
Liproxstatin-1 in Ferroptosis Research: Mechanistic Depth &
2026-06-22
Explore how Liproxstatin-1, a potent ferroptosis inhibitor, advances cell death research by revealing membrane-level regulatory mechanisms and translational potential. This article delivers a unique, in-depth analysis of Liproxstatin-1’s assay applications and mechanistic insights.
-
2,7-Dichlorodihydrofluorescein Diacetate: ROS Assay Workflow
2026-06-22
2,7-Dichlorodihydrofluorescein diacetate (DCFH-DA) enables sensitive, cell-permeable detection of intracellular ROS, unlocking quantitative studies in oxidative stress, mitochondrial dysfunction, and inflammation. This guide translates state-of-the-art research and troubleshooting into actionable protocols for fluorescence microscopy, flow cytometry, and plate-based assays.
-
LY294002: Precision PI3K/Akt/mTOR Inhibition for Advanced Ce
2026-06-21
LY294002 enables targeted, reversible inhibition of PI3K/Akt/mTOR signaling, distinguishing itself from older inhibitors with improved stability and dual BET bromodomain activity. Applied in both in vitro and in vivo systems, it empowers reproducible studies of apoptosis, autophagy, and disease modulation, as exemplified by its role in post-stroke cognitive impairment research.
-
One-step TUNEL Cy3 Apoptosis Detection Kit: Applied Protocol
2026-06-20
Discover how the One-step TUNEL Cy3 Apoptosis Detection Kit streamlines apoptosis detection across tissue and cell models, offering robust sensitivity, reproducibility, and workflow flexibility. Learn actionable protocol enhancements, troubleshooting strategies, and translational applications that make it indispensable for apoptosis research.
-
Tofacitinib Citrate (CP-690550) in Immune Regulation Researc
2026-06-19
Tofacitinib citrate (CP-690550 citrate) delivers precise, selective inhibition of JAK3, enabling nuanced modulation of immune and vascular pathways in advanced research models. This article unpacks stepwise workflows, comparative insights, and troubleshooting strategies to maximize reproducibility in immune regulation and inflammatory disorder research.
-
Redefining mCherry mRNA: Mechanistic Advances and Strategic
2026-06-19
This article explores the next-generation engineering of mCherry mRNA as a red fluorescent protein reporter, focusing on the mechanistic basis for Cap 1 capping and nucleotide modification (5mCTP, ψUTP) to minimize immune activation and maximize translational efficiency. It contextualizes emerging delivery strategies, such as lipid nanoparticles, referencing recent dermatological gene editing advances. The analysis delivers actionable guidance for translational researchers and frames the competitive landscape, highlighting how EZ Cap™ mCherry mRNA from APExBIO sets a new standard for robust, immune-evasive fluorescent labeling.
-
Glabridin-Gold(I) Complex Targets TrxR/MAPK to Boost Antitum
2026-06-18
This study introduces a novel glabridin-gold(I) (6d) complex that synergistically targets thioredoxin reductase and MAPK pathways to enhance antitumor immune responses while mitigating immunosuppression in liver cancer. The findings highlight new directions for metal-based immunomodulators in overcoming the tumor microenvironment's resistance to immunotherapy.